Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein L3 (APOL3)
- Target
- APOL3
- Molecular classification
- Lipid transporter, Membrane-interacting protein, Antibacterial innate immune factor, Other
01
Overview
Apolipoprotein L3 (APOL3) is a cytoplasmic lipid transporter and membrane-remodeling protein belonging to the apolipoprotein L family, encoded on human chromosome 22. Its main biological roles include regulating lipid distribution, promoting membrane fusion and fission events (critical for vesicle trafficking, apoptosis, and mitophagy), and defending cells against intracellular Gram-negative bacteria by detergent-like disruption of bacterial membranes—especially in response to inflammatory cytokines such as interferon-γ and TNF-α. APOL3 is highly expressed in kidney podocytes and vascular endothelial cells, where it modulates cytoskeletal organization via control of phosphatidylinositol-4-phosphate synthesis through interaction with PI4KB kinase and related factors. Dysfunction of APOL3 is linked to kidney pathologies (especially in podocytes), and it may play a role in inflammatory, metabolic, and retinal degenerative diseases. To date, APOL3 is not the direct target of any approved therapeutic drugs, but it is considered a relevant protein for host defense, cell biology, and disease associations.
- Other names
- ApoL-IIICG12_1CG12-1APOLIIIApolipoprotein L-IIITNF-inducible protein CG12-1CG121apoL-IIIapolipoprotein L3Apolipoprotein L, 3
02
Biological functions
Lipid transport within cytoplasmMembrane remodeling (fission and fusion)Induction of mitophagy and apoptosisRegulation of actomyosin cytoskeletonInnate immune response; bactericidal activityMembrane fusion with bacterial and host membranesCholesterol homeostasisSignal transduction (obsolete annotation)
03
Disease associations
Infection and host defense (intracellular bactericidal factor against pathogens like Salmonella)InflammationKidney disease, nephropathy (related to podocyte function and mutation/variants)Metabolic pathways (adipogenesis, angiogenesis) and cardiovascular disease (endothelial expression, atherosclerosis)Degenerative retinal diseases (Cone-Rod Dystrophy 3)
04
Safety considerations
Disruption may impair innate immunity to intracellular bacteriaLoss or mutation may cause kidney podocyte dysfunction, leading to nephropathyPotential off-target effects if modulating the protein, given key roles in apoptosis and mitophagy
05
Biomarkers
Expression level of APOL3 (for interferon response, kidney disease risk)Induced by TNF-alpha and interferon-γ in endothelial and non-immune cells
Beyond the preview
Go deeper on Apolipoprotein L3 (APOL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apolipoprotein L3 (APOL3).